Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma

被引：2
作者：
Ebia, Matthew I. [1 ]
Hitchins, Megan P. [2 ]
Hendifar, Andrew E. [1 ,3 ,4 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA USA
[3] Cedars Sinai Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
[4] Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, 8700 Beverly Blvd,Suite 1042AC, Los Angeles, CA 90048 USA
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2023年 / 14卷 / 02期
关键词：
Pancreatic ductal adenocarcinoma (PDAC); DNA deficient mismatch repair (DNA dMMR); microsatellite instability (MSI); Lynch syndrome; immunotherapy; CANCER;
D O I：
10.21037/jgo-23-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1175 / 1177
页数：3
相关论文
共 50 条
  • [31] Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
    Chen, Hao
    Yang, Gang
    Xiao, Jianchun
    Zheng, Lianfang
    You, Lei
    Zhang, Taiping
    CANCER LETTERS, 2020, 490 : 12 - 19
  • [32] Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
    Sarantis, Panagiotis
    Koustas, Evangelos
    Papadimitropoulou, Adriana
    Papavassiliou, Athanasios G.
    Karamouzis, Michalis, V
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (02) : 173 - 181
  • [33] Pediatric Rectal Adenocarcinoma With Mismatch Repair Deficiency Responds to Immunotherapy
    Qureshi, Naveen
    Hoffman, Trevor L.
    Kaneva, Kristiyana
    Zomorrodian, Sina
    Scapa, Jason V.
    Hitchins, Megan P.
    Federman, Noah
    JCO PRECISION ONCOLOGY, 2023, 7
  • [34] Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer
    Quiroga, Dionisia
    Lyerly, H. Kim
    Morse, Michael A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (08)
  • [35] Neoadjuvant treatment in locally advanced rectal cancer with deficient mismatch repair (dMMR): A paradigm shift
    Manuel-Vazquez, Alba
    Soria Tristan, Miguel
    Martin Martinez, Jose Miguel
    Ramos Rodriguez, Jose Luis
    CIRUGIA ESPANOLA, 2025, 103 (02): : 118 - 120
  • [36] Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies
    Pham, Thao N. D.
    Shields, Mario A.
    Spaulding, Christina
    Principe, Daniel R.
    Li, Bo
    Underwood, Patrick W.
    Trevino, Jose G.
    Bentrem, David J.
    Munshi, Hidayatullah G.
    CANCERS, 2021, 13 (03) : 1 - 22
  • [37] The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy
    Hilmi, Marc
    Delaye, Matthieu
    Muzzolini, Milena
    Nicolle, Remy
    Cros, Jerome
    Hammel, Pascal
    Cardot-Ruffino, Victoire
    Neuzillet, Cindy
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (12): : 1129 - 1142
  • [38] Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors
    Auclin, Edouard
    Vuagnat, Perrine
    Smolenschi, Cristina
    Taieb, Julien
    Adeva, Jorge
    Nebot-Bral, Laetitia
    Garcia de Herreros, Marta
    Vidal Tocino, Rosario
    Longo-Munoz, Federico
    El Dakdouki, Yola
    Martin-Romano, Patricia
    Gaba, Lydia
    Sauri, Tamara
    Oliveres, Helena
    Castanon, Eduardo
    Garcia-Carbonero, Rocio
    Besse, Benjamin
    Massard, Christophe
    Mezquita, Laura
    Hollebecque, Antoine
    CANCERS, 2021, 13 (15)
  • [39] Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?
    Smith, Henry
    Arbe-Barnes, Edward
    Shah, Enas Abu
    Sivakumar, Shivan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [40] Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
    Balsano, Rita
    Zanuso, Valentina
    Pirozzi, Angelo
    Rimassa, Lorenza
    Bozzarelli, Silvia
    CURRENT ONCOLOGY, 2023, 30 (04) : 3871 - 3885
12345